Residual renal function modulates response to erythropoietin in chronic renal insufficiency

Dialysis and Transplantation

Volumn 30, Issue 6, 2001, Pages 344-354

  Ifudu, O ^a   Cohen, L S ^a   Mayers, J D ^a   Joseph, A ^a   Delano, B G ^a   Friedman, E A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; NITROGEN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UREA;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEMATOCRIT; HUMAN; INJECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; TRANSFERRIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

EID: 0034981352     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin
2. Anemia during the predialysis period: A key to cardiac damage in renal failure
3. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
4. Left ventricular hypertrophy in renal failure
5. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
6. Hematocrit level and associated mortality in hemodialysis patients
7. Cardiovascular effects of recombinant human erythropoietin in predialysis patients
8. Erythropoietin in diabetic macular edema and renal insufficiency
9. The relationship between hemoglobin levels and diabetic retinopathy
10. Renal function in predialysis children with chronic renal failure treated with erythropoietin
11. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients
12. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial
13. Effectiveness and safety of recombinant human erythropoietin (r·HuEPO) in the treatment of anemia of chronic renal failure in non-dialysis patients - European Multicenter Study Group
14. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease
15. Severity of acquired immunodeficiency syndrome and the response to erythropoietin in uremia
16. Anemia in hemodialysis patients: Variables affecting this outcome predictor
17. Prediction of creatinine clearance from serum creatinine
18. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis
19. Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction
20. Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure
21. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure
22. Effect of erythropoietin in normal men and in patients with renal insufficiency
23. Erythropoietin levels in uremic nephric and anephric patients
24. Exceptionally high serum erythropoietin activity in an anephric patient with severe anemia
25. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure
26. Disorders of red blood cell production in uremia
27. Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis
28. Polyamines in the anemia of end-stage renal disease
29. Response of uremic bone marrow cells to erythropoietin in vitro
30. Anemia of the regular hemodialysis patient and its treatment
31. Effect of dialysis therapy on the hematopoietic system: The National Cooperative Dialysis Study
32. Effect of increased hemodialysis dose on endogenous erythropoietin production in end-stage rena disease
33. Relative contributions of body iron stares and uremia severity to anemia in patients with advanced chronic renal failure
34. Delayed referral of black, Hispanic, and older patients with chronic renal failure